Formerly the Co-Founder & Director of the Microbiome Movement Series at Hanson Wade, Mo has led the global pharmaceutical market segment at CosmosID since 2018. His role involves the support of R&D scientists and biotech executives in deploying microbial genomics throughout the drug development pipeline, including pre-clinical, clinical and CMC applications. Mo has led a number of partnerships and collaborations with big pharma, biotech and CRO’s in the incorporation of metagenomics in phase I, II and III clinical trials for the purpose of developing novel therapeutics and diagnostics.
Microbial Profiling Showcase:
CosmosID® is a global leader in supporting the pharmaceutical sector with CLIA-certified, ICH-GCP compliant microbiome and microbial isolate solutions for applications such as pre-clinical, clinical, CMC and regulatory support.
Supporting Drug Development with Microbiome Solutions
Robust, standardised, and validated workflows are crucial for controlling the introduction of bias. Deriving clinically actionable and informative results from shotgun metagenomic sequencing data requires modern bioinformatics and database solutions to accurately delineate microbial communities down to strain-level.
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.